Related Experiment Video
Updated: Aug 25, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Signaling through the epidermal growth factor receptor during the development of malignancy
Jennifer Rubin Grandis1, John C Sok
1Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. jgrandis@pitt.edu
Abstract:
The epidermal growth factor receptor (EGFR) is overexpressed and/or constitutively activated in a variety of human malignancies. Detection of increased expression levels of EGFR in cancer and the association between overexpression and decreased patient survival has led to the development of several therapeutic strategies to target this receptor. The results of early-phase clinical trials to date suggest that targeting EGFR alone may not be sufficient to eradicate established tumors. This limited antitumor efficacy as monotherapy has led to combining EGFR inhibitors with chemotherapy or radiation therapy for advanced disease, or incorporating EGFR inhibition to cancer prevention approaches. This review will discuss the role of EGFR signaling in carcinogenesis and the rationale for EGFR inhibition as a clinical prevention and treatment strategy.
Insights
Epidermal growth factor receptor (EGFR) is often overexpressed in cancers, driving tumor growth. Targeting EGFR shows promise but often requires combination therapies for effective cancer treatment and prevention.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Epidermal growth factor receptor (EGFR) is frequently overexpressed and activated in various human cancers.
- Elevated EGFR levels correlate with poorer patient survival, establishing it as a key therapeutic target.
Purpose of the Study:
- To review the role of EGFR signaling in the development of cancer.
- To discuss the rationale and strategies for inhibiting EGFR in cancer prevention and treatment.
Main Methods:
- Literature review of studies on EGFR signaling in carcinogenesis.
- Analysis of clinical trial data for EGFR inhibitors as monotherapy and in combination treatments.
Main Results:
- EGFR overexpression is a common feature in many malignancies.
- EGFR inhibitors as monotherapy have shown limited efficacy in eradicating established tumors.
- Combination strategies involving EGFR inhibitors with chemotherapy, radiation, or for cancer prevention are being explored.
Conclusions:
- EGFR signaling is a critical driver in carcinogenesis.
- Targeting EGFR is a key strategy in cancer therapy and prevention.
- Combination approaches are essential for maximizing the clinical benefit of EGFR inhibition.
Related Concept Videos
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Autocrine Signaling
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...

